Current Management of Hepatitis C Virus, An Issue of Clinics in Liver Disease
1. Auflage
Erschienen am 7. Januar 2016
100 Seiten
978-0-323-41337-4 (ISBN)
Beschreibung
Clinical information about Hepatitis C is quickly outdated, so Dr. Poordad has assembled expert authors to provide state-of-the-art clinjcal reviews for hepatologists. This issue is uniquely organized to present articles based on therapeutic regimens for certain types of patients:
Regimens for the Treatment-Naïve Patient; Regimens for Treatment of the Interferon-Failure Patient; Regimens for DAA Failure Patients; Regimens for the Cirrhotic Patient; Regimens for the Peri-Transplant Patient; Regimens for the HIV-Co-Infected Patient; and Next-generation Regimens: The Future of HCV Therapy. This presentation will be very clinically relevant for the practicing hepatologist.
Regimens for the Treatment-Naïve Patient; Regimens for Treatment of the Interferon-Failure Patient; Regimens for DAA Failure Patients; Regimens for the Cirrhotic Patient; Regimens for the Peri-Transplant Patient; Regimens for the HIV-Co-Infected Patient; and Next-generation Regimens: The Future of HCV Therapy. This presentation will be very clinically relevant for the practicing hepatologist.
Weitere Details
Weitere Ausgaben
Inhalt
- Front Cover
- Current Management of Hepatitis C Virus
- Copyright
- Contributors
- CONSULTING EDITOR
- EDITOR
- AUTHORS
- Contents
- Preface: Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician
- Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era
- Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses
- Regimens for the Hepatitis C Treatment-Naive Patient
- Direct-Acting Antiviral Agents: Regimens for the Interferon Failure Patient
- Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment
- Regimens for Cirrhotic Patients
- Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients
- Regimens for Patients Coinfected with Human Immunodeficiency Virus
- Next-Generation Regimens: The Future of Hepatitis C Virus Therapy
- CLINICS IN LIVER DISEASE
- FORTHCOMING ISSUES
- February 2016
- May 2016
- August 2016
- RECENT ISSUES
- August 2015
- May 2015
- February 2015
- Preface: Hepatitis C Therapy: Simple for the Patient, not so Simple for the Clinician
- Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era
- Key points
- INTRODUCTION
- SCREENING
- CLINICAL EVALUATION
- Pretreatment Investigations
- Hepatitis C Virus Investigations
- Other Investigations
- Fibrosis Staging
- DRUG-DRUG INTERACTIONS
- COUNSELING
- WHEN TO TREAT
- SUMMARY
- REFERENCES
- Meet the Classes of Directly Acting Antiviral Agents
- Key points
- INTRODUCTION
- THE HEPATITIS C VIRUS LIFE CYCLE
- VIRAL ENTRY
- VIRAL REPLICATION
- THE ISSUE OF POLYMORPHISMS AND DRUG RESISTANCE
- NS3/4A PROTEASE INHIBITORS
- NS5A INHIBITORS
- NS5B POLYMERASE INHIBITORS
- Nucleoside/Nucleotide Analogue Inhibitors of Hepatitis C Virus NS5B Polymerase
- NON-NUCLEOSIDE INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE
- THE RATIONALE BEHIND COMBINATION THERAPY
- SUMMARY
- REFERENCES
- Regimens for the Hepatitis C Treatment-Naive Patient
- Key points
- INTRODUCTION
- TREATMENT IN NAIVE PATIENTS WITHOUT CIRRHOSIS
- Hepatitis C Virus Genotype 1
- Hepatitis C Virus Genotype 2
- Hepatitis C Virus Genotype 3
- TREATMENT IN NAIVE PATIENTS WITH CIRRHOSIS
- Hepatitis C Virus Genotype 1
- Hepatitis C Virus Genotype 2
- Hepatitis C Virus Genotype 3
- TREATMENT OF HEPATITIS C VIRUS GENOTYPE 4 INFECTION
- TREATMENT OF HEPATITIS C VIRUS GENOTYPE 5 AND 6 INFECTION
- FUTURE THERAPY
- SUMMARY
- REFERENCES
- Direct-Acting Antiviral Agents
- Key points
- INTRODUCTION
- HISTORY OF INTERFERON-CONTAINING REGIMENS
- INTERFERON INTOLERABILITY
- INTERFERON FAILURE
- Currently Recommended Treatment Regimens for Interferon Failure Patients: A Review of the Evidence and Current Guidelines
- GENOTYPES 1A AND 1B TREATMENT RECOMMENDATIONS
- GENOTYPES 2 AND 3 TREATMENT RECOMMENDATIONS
- GENOTYPES 4, 5, AND 6 TREATMENT RECOMMENDATIONS
- SUMMARY
- REFERENCES
- Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment
- Key points
- INTRODUCTION
- MECHANISMS OF DIRECT-ACTING ANTIVIRAL DRUGS
- Protease Inhibitors
- NS5A Inhibitors
- NS5B Non-nucleoside Polymerase Inhibitors
- NS5B Nucleoside Polymerase Inhibitors
- POTENTIAL FAILURE POPULATIONS
- Mono-Direct-Acting Antiviral Therapy with Protease Inhibitor
- Mono-Sofosbuvir Failures
- All Oral Treatment Failures
- MECHANISM OF NONRESPONSE TO ANTIVIRAL
- Viral Factors
- Host Factors
- Altered Pharmacokinetics
- Portosystemic Shunting and Cirrhosis
- THERAPEUTIC OPTIONS FOR RETREATMENT OF DIRECT-ACTING ANTIVIRAL FAILURES
- Clinical Trials Inclusive of Sofosbuvir Failures in Genotype 1
- Retreatment of Sofosbuvir Failures with Genotype 2 or 3
- Approach to Patients Requiring Retreatment
- Cocktail Mixology for Hepatitis C Virus
- SUMMARY
- REFERENCES
- Regimens for Cirrhotic Patients
- Key points
- TREATMENT OPTIONS: GENOTYPE 1
- Treatment Options for Genotype 1 Individuals Who Have Failed Previous Therapy
- GENOTYPE 2
- GENOTYPE 3
- GENOTYPE 4
- GENOTYPES 5 AND 6
- REFERENCES
- Current Management of Hepatitis C Virus
- Key points
- INTRODUCTION
- HEPATITIS C VIRUS TREATMENT BEFORE LIVER TRANSPLANT TO ACHIEVE CURE
- HEPATITIS C VIRUS TREATMENT BEFORE LIVER TRANSPLANT TO PREVENT HEPATITIS C VIRUS RECURRENCE
- PREEMPTIVE HEPATITIS C VIRUS TREATMENT AFTER LIVER TRANSPLANT TO ACHIEVE CURE
- HEPATITIS C VIRUS TREATMENT AFTER LIVER TRANSPLANT TO ACHIEVE CURE
- Significant Fibrosis/Compensated Cirrhosis
- Decompensated Cirrhosis
- PRETRANSPLANT VERSUS POSTTRANSPLANT THERAPY: WHICH IS BETTER?
- Wait-Listed Patients
- Post-Liver Transplant Recipients
- SUMMARY
- REFERENCES
- Regimens for Patients Coinfected with Human Immunodeficiency Virus
- Key points
- INTRODUCTION
- Epidemiology and Natural History of Hepatitis C Virus in Patients with Human Immunodeficiency Virus 1
- Special Consideration in Evaluation of Patients Coinfected with Human Immunodeficiency Virus
- Treatment of Hepatitis C Virus in Patients with Human Immunodeficiency Virus Using Interferon-containing Regimens
- Antiretroviral Therapy Considerations and Drug-Drug Interactions
- Current Regimens for Hepatitis C Virus Genotype 1 Treatment in Patients with Human Immunodeficiency Virus 1
- Nucleotide-based Hepatitis C Virus Treatment Regimens
- Sofosbuvir plus interferon
- Sofosbuvir plus RBV
- Sofosbuvir-antiretroviral drug interactions
- Sofosbuvir plus an NS5A inhibitor
- NS5A inhibitor drug interactions and implications for sofosbuvir/NS5A regimens
- Sofosbuvir plus an NS3 protease inhibitor
- NS3 protease inhibitor-based regimens
- Human Immunodeficiency Virus Control During Direct-acting Antiviral Therapy
- SUMMARY
- REFERENCES
- Next-Generation Regimens
- Key points
- INTRODUCTION
- LIMITATIONS OF PAST REGIMENS
- PHASE III TRIALS
- Daclatasvir/Asunaprevir/Beclabuvir
- Daclatasvir/Sofosbuvir
- PHASE II TRIALS
- Grazoprevir (MK-5172)/Elbasvir (MK-8742)
- GS-5816/Sofosbuvir
- ACH-3102
- PHASE I
- ABT-493/ABT-530
- MK-3682 (Formally IDX21437)
- PRECLINICAL AGENTS
- MK-8408
- HOST TARGETED AGENTS
- MIRAVIRSEN
- RG-101
- FUTURE FRONTIERS
- REFERENCES
